Mainz Biomed Pushes for Colorectal Cancer Prevention

During Colorectal Cancer Awareness Month, Mainz Biomed N.V. emphasizes a shift from screening to prevention of colorectal cancer (CRC). The company, listed on NASDAQ as MYNZ, focuses on early cancer detection, advocating proactive strategies over late-stage diagnostics. With CRC being the second leading cause of cancer deaths globally, Mainz Biomed's mission is crucial.

Their approach integrates mRNA biomarkers, a FIT test, and AI, showing a remarkable 82% advanced adenoma detection sensitivity. This method highlights potential advantages for early intervention. Mainz Biomed's flagship product, ColoAlert®, is already enhancing global CRC screening accessibility, including recent partnerships in Switzerland.

Mainz Biomed is committed to advancing at-home testing solutions, aiming to lower screening barriers and empower individuals. The company supports education, innovation, and accessibility to boost early detection rates, ultimately aiming for prevention of colorectal cancer.